SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company focused on modulating lipid signaling pathways to develop treatments for people with cancer, pain and neurological disorders, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, presented new research results titled, “Discovery and preclinical evaluation of a new FABP5 inhibitor, ART26.12, effective in chemotherapy-induced pain”, during the opening oral session of the symposium from the International Cannabinoid Research Society (ICRS).
“Our preclinical research showed that chronic oral treatment with ART26.12, our primary FABP5 inhibitor, was effective in both preventing and treating oxaliplatin and paclitaxel-induced pain sensitivity without any sedative effects” , said Professor Saoirse O’Sullivan. “In prevention studies, ART26.12 also minimized acute weight loss caused by oxaliplatin. These results support the further development of ART26.12 in chemotherapy-associated neuropathy and other neuropathies,” said continued Professor O’Sullivan.
Chemotherapy-induced peripheral neuropathy, also known as CIPN, is a common and often painfully debilitating complication of cancer treatments, sometimes leading to treatment reduction or discontinuation. For some cancer patients, CIPN may persist long after chemotherapy has stopped. In preclinical models of CIPN, inhibition of fatty acid binding protein 5 (FABP5) has demonstrated positive activity in analgesia, enhancing the effects of CIPN, a condition for which no currently approved treatment exists. .
“Developing therapies for CIPN represents an exciting new opportunity for Artelo’s FABP5 inhibitors,” said Gregory D. Gorgas, President and CEO of Artelo Biosciences. “As we continue to develop our FABP inhibitors in cancer and anxiety, based on these latest research results at CIPN, we intend to meet with the FDA for a pre-IND consultation on ART26 .12 before the end of this year.”
The ICRS Symposium is being held at Bailey Allen Hall, National University of Ireland, Galway, 25-30 June 2022.
Fatty acid binding proteins (FABPs) are a family of intracellular proteins that chaperone lipids, including endocannabinoids and fatty acids. Various FABP inhibitors may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a selective FABP5 inhibitor. During the development of our lead molecule for chemotherapy-induced peripheral neuropathy, additional compounds from our extensive library of potent and selective FABP inhibitors were identified and selected for progress to regulatory enabling studies in cancer and other areas of high unmet need where FABP inhibition holds great promise.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo offers a portfolio of broadly applicable product candidates designed to address significant unmet needs across multiple diseases and conditions, including anorexia, cancer, anxiety, pain and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies cutting-edge scientific, regulatory and business discipline to develop high-impact therapies. More information is available on www.artelobio.com and Twitter: @ArteloBio.
About the International Cannabinoid Research Society
The International Cannabinoid Research Society (ICRS) is the world’s premier scientific association with over 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source of unbiased information on cannabis and cannabinoids, ICRS’ primary role is to provide an open forum for researchers to meet and discuss their research. Interested parties can follow @ICRS_Society and @sciencesaoirse on Twitter and use #ICRS2022 for the latest meeting updates.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to product development of the Company, clinical and regulatory timelines, market opportunities, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements of a predictive nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate, as well as management’s current beliefs and assumptions. These statements can be identified by the use of forward-looking expressions, including, but not limited to, “expect”, “anticipate”, “intend”, “plan”, “believe”. , “estimate”, “potential”, “predict”, “project”, “should”, “would” and similar expressions and the negatives of these terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from the results, performance or achievements future expressed or implied by the forward-looking statements. research statements. These factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as to the extent required by applicable securities laws.
Contact with Investor Relations:
Crescendo Communications, LLC
E-mail: [email protected]